Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Kamada has successfully completed Phase I clinical studies designed to test the safety and tolerability of the aerosolized version of its flagship product, Alpha-1 Antitrypsin using an optimized eFlow electronic nebulizer to treat various lung diseases.
Subscribe to our email newsletter
Kamada has already obtained orphan drug designation from both the FDA and the EMEA for aerosolized Alpha-1 Antitrypsin (AAT) for the treatment of congenital emphysema and cystic fibrosis.
David Tsur, CEO of Kamada, said: “Kamada is strategically progressing towards registration of its AAT formulations in the European and US markets.”